Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075373 | 0.82 | CYP2A6 (0.62) | CYP2A6ACHETDP1RAB9ANPC1 | |
| SCHEMBL1059707 | 0.82 | CYP2A6 (0.48) | CYP2A6ACHETDP1RAB9ANPC1 | |
| SCHEMBL318785 | 0.79 | NFE2L2 (0.74) | CYP2A6ACHETDP1RAB9ANPC1 | |
| SCHEMBL1149391 | 0.79 | CYP2A6 (0.58) | CYP2A6ACHETDP1RAB9ANPC1 | |
| (E)-1,2-Di-P-Tolylethene SCHEMBL1305582 | 0.79 | NFE2L2 (0.74) | CYP2A6ACHETDP1RAB9ANPC1 | |
| (E)-1,2-Di-P-Tolylethene SCHEMBL1305580 | 0.79 | NFE2L2 (0.74) | CYP2A6ACHETDP1RAB9ANPC1 | |
| SCHEMBL318786 | 0.79 | NFE2L2 (0.74) | CYP2A6ACHETDP1RAB9ANPC1 | |
| (E)-1,2-Di-P-Tolylethene SCHEMBL1793692 | 0.79 | NFE2L2 (0.74) | CYP2A6ACHETDP1RAB9ANPC1 | |
| SCHEMBL137714 | 0.76 | — | — | |
| P-Xylene SCHEMBL460348 | 0.76 | ACHE (1.00) | CYP2A6ACHETDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878701-B2 | Potassium channel blocking agents | NEUROSEARCH A/S (DK) | 2005-04-12 | — | — | US | claimed |
| US-20020137784-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-09-26 | — | — | US | claimed |
| US-20020128279-A1 | Potassium channel blocking agents | NEUROSEARCH A/S (DK) | 2002-09-12 | — | — | US | claimed |
| US-6380180-B1 | BENZIMIDAZOLE COMPOUNDS FOR TREATMENT OF ASTHMA, VASOSPASM, MEMORY LOSS, MIGRAINE AND OTHERS DISEASES ASSOCIATED WITH POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2002-04-30 | — | — | US | claimed |
| US-20020049246-A1 | Potassium channel blocking agents | NEUROSEARCH A/S | 2002-04-25 | — | — | US | claimed |
| EP-1196419-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2002-04-17 | — | — | EP | claimed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | claimed |
| US-6194447-B1 | ASTHMA, ANTICONVULSANTS, COGNITION ACTIVATORS, BRAIN DISORDERS, PSYCHOLOGICAL DISORDERS, CARDIOVASCULAR DISORDERS,GASTROINTESTINAL DISORDERS | NEUROSEARCH A/S (DK) | 2001-02-27 | — | — | US | claimed |
| WO-2001002406-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-01-11 | — | — | WO | claimed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | claimed |
| US-6878701-B2 | Potassium channel blocking agents | NEUROSEARCH A/S (DK) | 2005-04-12 | — | — | US | disclosed |
| US-6569880-B2 | Guanidine derivatives | NEUROSEARCH A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| US-20020128279-A1 | Potassium channel blocking agents | NEUROSEARCH A/S (DK) | 2002-09-12 | — | — | US | disclosed |
| US-6380180-B1 | BENZIMIDAZOLE COMPOUNDS FOR TREATMENT OF ASTHMA, VASOSPASM, MEMORY LOSS, MIGRAINE AND OTHERS DISEASES ASSOCIATED WITH POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| EP-1196419-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2002-04-17 | — | — | EP | disclosed |
| EP-1091942-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-04-18 | — | — | EP | disclosed |
| US-6194447-B1 | ASTHMA, ANTICONVULSANTS, COGNITION ACTIVATORS, BRAIN DISORDERS, PSYCHOLOGICAL DISORDERS, CARDIOVASCULAR DISORDERS,GASTROINTESTINAL DISORDERS | NEUROSEARCH A/S (DK) | 2001-02-27 | — | — | US | disclosed |
| WO-2001002406-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000001676-A1 | POTASSIUM CHANNEL BLOCKING AGENTS | NEUROSEARCH A/S (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128279-A1 | Potassium channel blocking agents | KCND2, KCNJ2, KCNN3 | CYP2A6 4750/4885ACHE 190/4885TDP1 338/4885 |
| US-20020137784-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | CYP2A6 4581/4885ACHE 162/4885TDP1 469/4885 |
| US-20020049246-A1 | Potassium channel blocking agents | KCNH2, KCNH3, KCND2 | CYP2A6 4581/4885ACHE 162/4885TDP1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.